Zydus gets USFDA nod for chemotherapy drug
The drug will be produced at the group's manufacturing facility in Ahmedabad18-01-2017
18-01-2017
Board Meeting Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on January 30, 2017 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will...12-01-2017
Shareholding for the Period Ended December 31, 2016
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here09-01-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.08-01-2017
Zydus acquires six brands from US pharma player MSD
Recalls over 16,000 bottles of depressive disorder drug in US28-12-2016
Appointment of Additional Independent Director
Zydus Wellness Ltd has informed BSE that Mr. Kulin Lalbhai is appointed as an Additional Independent Director of the Company for a period of five consecutive years, subject to approval of the members at the ensuing Annual General Meeting.18-11-2016
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Pankaj R Patel has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 201118-11-2016
Cadila to transfer India human formulations business to Zydus
The India human formulations business, including a manufacturing plant at GIDC, Ahmedabad and pharmaceutical technology centre in Ahmedabad will be transferred to Zydus17-11-2016
Investor Presentation
Zydus Wellness Ltd has submitted to BSE a copy of the investor presentation to be made by Mr. Tarun G. Arora, Whole Time Director and Mr. Amit B. Jain, Chief Financial Officer of the Company to the select investors on November 16, 2016 in Grand Hyatt, Kalina, Mumbai.15-11-2016
Zydus Wellness Q2 Net up 10.2% to Rs 32 crore
Gross margins increased by 140 basis points and reached 66.8 per cent25-10-2016